Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases.
Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 14, 24 | 0 Increased by +100% | - |
| Dec 5, 23 | -0.04 Increased by +73.79% | - |
| Jul 25, 23 | -0.07 Decreased by -27.72% | - |
| May 31, 23 | -0.17 Decreased by -1.4 K% | - |
| Mar 16, 23 | -0.14 Decreased by -134.65% | - |
| Dec 6, 22 | -0.15 Decreased by -0.13% | - |
| Jul 26, 22 | -0.05 Decreased by -3.39 K% | - |
| Jun 1, 22 | 0.01 Increased by +690.91% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -215 K Increased by +84.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -364 K Decreased by -1.96% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -1.56 M Decreased by -223.87% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | -459 K Decreased by -131.31% | -1.3 M Decreased by -162.1% | Increased by +283.44% Increased by +98.34% |
| Sep 30, 22 | 0 Decreased by N/A% | -1.43 M Decreased by -180% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -357 K Increased by +58.73% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | 1.26 M Increased by +340.91% | Increased by +N/A% Decreased by N/A% |
| Dec 31, 21 | 1.47 M Increased by +5.14 K% | 2.1 M Increased by +921.95% | Increased by +142.91% Decreased by -80.48% |